SNIPR Biome Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001

Written by Christian Mygind

SNIPR001 is the company’s first development candidate targeting E. coli in patients with hematological malignancy at risk of neutropenia.

Press Release
Mediawatch Article
Christian Mygind
Previous

SNIPR Biome announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark